佐力藥業(300181.SZ):參股公司科濟藥業遞交聯交所上市申請
格隆匯 2 月 28日丨佐力藥業(300181.SZ)公佈,近日,公司從香港聯交所網站查詢(https://www.hkex.com.hk)獲悉,公司孫公司浙江佐力創新醫療投資管理有限公司參股公司 CARsgen Therapeutics Holdings Limited(以下簡稱"科濟藥業")於2021年2月26日向香港聯交所遞交了上市申請。同日,香港聯交所網站刊登了科濟藥業發行上市的申請資料,該申請資料按照香港證券及期貨事務監察委員會(以下簡稱"香港證監會")及香港聯交所的要求編制和刊發,為草擬版本,其所載資料可能會適時作出更新和變動。
科濟藥業是一家在中國及美國運營的臨牀階段的生物製藥公司,專注於治療實體瘤和血液惡性腫瘤的創新細胞療法。科濟藥業已內部開發突破性技術以及擁有全球權利的革命性產品,以解決 CAR-T 細胞療法的重大挑戰,其使命是成為能為全球癌症患者帶來創新和差異化的細胞療法並使癌症可治癒的全球生物製藥的領導者。截至本公吿日,科濟藥業已在中國、美國和加拿大獲得 7 個 CAR-T療法的 IND 批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.